RESUMO
Hepatitis B virus causes acute and chronic infections in millions of people worldwide and, since 1982, a vaccine with 95% effectiveness has been available for immunization. The main component of the recombinant hepatitis B vaccine is the surface antigen protein (HBsAg). In this work, the effect of pH, ionic strength and temperature on the native state of the HBsAg antigen were studied by a combination of biophysical methods that included small angle X-ray scattering, synchrotron radiation circular dichroism, fluorescence and surface plasmon resonance spectroscopies, as well as in vivo and in vitro potency assays. The native conformation, morphology, radius of gyration, and antigenic properties of the HBsAg antigen demonstrate high stability to pH treatment, especially in the pH range employed in all stages of HBsAg vaccine production and storage. The HBsAg protein presents thermal melting point close to 56°C, reaching a more unfolded state after crossing this point, but it only experiences loss of vaccine potency and antigenic properties at 100°C. Interestingly, a 6-month storage period does not affect vaccine stability, and the results are similar when the protein is kept under refrigerated conditions or at room temperature (20°C). At frozen temperatures, large aggregates (>200nm) are formed and possibly cause loss of HBsAg content, but that does not affect the in vivo assay. Furthermore, HBsAg has a well-ordered secondary structure content that is not affected when the protein is formulated with silica SBA-15, targeting the oral delivery of the vaccine. The combined results from all the characterization techniques employed in this study showed the high stability of the antigen at different storage temperature and extreme values of pH. These findings are important for considering the delivery of HBsAg to the immune system via an oral vaccine.
RESUMO
Objective: To evaluate the applicability of SBA-15 silica as an adjuvant in immunizations with purified particles of the viral protein HBsAg, the main component of hepatitis B vaccine, Butang®, produced by Instituto Butantan. Methods: BALB/c mice orally or subcutaneously received 0.5 mug of HBsAg adsorbed/encapsulated to SBA-15 or adsorbed to Al(OH)3. To assess the secondary immune response, a subcutaneous booster was administered 30 days after the first immunization. Individual serum and fecal samples of each group were periodically collected for specific antibody titration by ELISA. Results: Analysis of secretory IgA showed that mice orally primed with HBsAg on SBA-15 had increased levels of specific antibodies in primary and secondary immune responses. Specific serum IgA and IgG titers in HBsAg:SBA-15-orally immunized mice reached higher levels after the booster, demonstrating the effectiveness of oral vaccination with the use of silica. All immunized groups showed higher IgG1 levels. Conclusion: Our results clearly indicate the promising use of SBA-15 as an adjuvant, especially in oral immunizations.
Objetivo: Demonstrar a aplicabilidade da sílica do tipo SBA-15 como adjuvante nas imunizações com a proteína recombinante HBsAg do vírus da hepatite B, principal componente da vacina Butang® produzida pelo Instituto Butantan. Métodos: Camundongos BALB/c receberam, pela via oral ou subcutânea, 0,5 mig do HbsAg adsorvido/encapsulado à SBA-15 ou adsorvido ao Al(OH)3. Para avaliar a resposta imune secundária, uma dose de reforço foi administrada subcutaneamente 30 dias após a primeira imunização. Amostras individuais de soro e fezes foram coletadas periodicamente para titulação de anticorpos específicos por ELISA. Resultados: A análise de IgA secretada mostrou que camundongos imunizados pela via oral com HbsAg em SBA-15 apresentaram aumento nos níveis de anticorpos específicos nas respostas primária e secundária. Ainda, após o reforço, observaram-se maiores níveis de IgA e IgG séricas anti-HBsAg no grupo preparado com HBsAg:SBA-15 pela via oral. Todos os grupos imunizados apresentaram maior produção de IgG1. Conclusão: Os resultados indicam o uso promissor da sílica SBA-15 como adjuvante, especialmente nas imunizações pela via oral.
Assuntos
Adjuvantes Imunológicos , Hepatite B , Memória ImunológicaRESUMO
OBJECTIVE: To evaluate the applicability of SBA-15 silica as an adjuvant in immunizations with purified particles of the viral protein HBsAg, the main component of hepatitis B vaccine, Butang®, produced by Instituto Butantan. METHODS: BALB/c mice orally or subcutaneously received 0.5 µg of HBsAg adsorbed/encapsulated to SBA-15 or adsorbed to Al(OH)3. To assess the secondary immune response, a subcutaneous booster was administered 30 days after the first immunization. Individual serum and fecal samples of each group were periodically collected for specific antibody titration by ELISA. RESULTS: Analysis of secretory IgA showed that mice orally primed with HBsAg on SBA-15 had increased levels of specific antibodies in primary and secondary immune responses. Specific serum IgA and IgG titers in HBsAg:SBA-15-orally immunized mice reached higher levels after the booster, demonstrating the effectiveness of oral vaccination with the use of silica. All immunized groups showed higher IgG1 levels. CONCLUSION: Our results clearly indicate the promising use of SBA-15 as an adjuvant, especially in oral immunizations.
RESUMO
Três lotes de vacinas contra o sarampo, produzidos com a cepa de vírus Biken CAM-70, sob as formas liofilizada e reconstituída, pertencentes ao estoque da rede de vacinaçäo da Secretaria de Estado da Saúde de Säo Paulo, Brasil, foram submetidos a testes de sensibilidade a luz, a temperatura de 2 a 8§C, e de termoestabilidade (protegidos da luz) as temperaturas de 28, 36,5 e 45§C, objetivando verificar por quanto tempo retinham sua potência, isto é, a concentraçäo ideal recomendada para a cepa de vírus presente. A análise de retas de regressäo ajustadas demonstrou que, de modo geral, tanto os lotes de vacinas liofilizados como de potência no decorrer do experimento, a qual foi mais acentuada para vacinas expostas a luz. Reconstituídos e mantidos a 2 a 8§C, os lotes näo apresentaram homogeneidade no referente a sensibilidade a luz. Quando a fotossensibilidade de lotes de vacinas liofilizadas foi testada a 2 a 8§C eles mostraram-se mais sensíveis a degradaçäo térmica quando expostos a luz do que quando protegidos dela. Entretanto, expostos ou protegidos, a potência foi inferior a mínima aceita para a cepa Bikien CAM-70. As demais temperaturas, mesmo ao abrigo da luz, os dois lotes näo retiveram potência mínima. Quanto as vacinas do lote 3, conservadas a 2 a 8§C, mantiveram-se de acordo com os requerimentos mínimos de potência durante 60 dias quando protegidas da luz, e durante 40 dias quando expostas a ela. A degradaçäo térmica as demais temperaturas foi mais acentuada (28§C: 5 dias...